Truscreen Group Ltd. · NZX:TRU
Truscreen — Investor Presentation (May 2026)
37 slides from Truscreen's investor presentation, May 21, 2026
Slide 1: Investor Presentation May 2026
For personal use only Investor Presentation May 2026
Slide 2: Disclaimer and important notice
Disclaimer and important notice This presentation has been prepared by TruScreen Group Limited (TRU). This presentation has been prepared in relation to the offer of new shares in TRU (New Shares) by way of a: • Placement to selected investors in certain jurisdictions (Placement); and • A 1 for 5 Ri
Slide 3: Disclaimer and important notice (Continued)
Disclaimer and important notice (Continued) Future performance (continued): The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no obligation to
Slide 4: Disclaimer and important notice (continued)
Disclaimer and important notice (continued) Distribution of presentation: This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of an
Slide 5: For personal use only
• Who is TruScreen • The TruScreen Technology For personal use only • The Global Cervical Cancer Screening Market • Why TruScreen • TruScreen Sales and Growth Strategy
Slide 6: Who is TruScreen
For personal use only Who is TruScreen Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution
Slide 7: TruScreen Group Ltd overview
TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device. For personal use only FY26 annual sales exceeded NZD $2.4m - 42% YOY growth. TruScreen Group Ltd owns TruScreen Pty Ltd, the Australian operating company that manufa
Slide 8: Share Price History
Share Price History TRU.NZ For personal use only TruScreen Group Ltd is listed on Market Capitalisation at 11 May 2026: Shares on Issue: the Australian (ASX) and New NZD $13.45m 747,325,326 Zealand (NZX) stock exchanges, with a common ticker code of TRU. 8
Slide 9: Corporate Snapshot and Major Shareholders
Corporate Snapshot Major Shareholders Market cap NZD$ 13.45m Shareholder Shares % Share price NZD$ 0.018 New Zealand Depository Nominee 110,486,503 14.78 52 week high NZD$ 0.030 New Zealand Central Securities 31,885,021 4.27 For personal use only 52 week low NZD$ 0.016 HSBC Custody Nominees 30,385,4
Slide 10: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond For personal use only 2017 Dec 2018 Oct 2019 May 2022 2025 CFDA (NMPA) 523% sales Recognition by Managing COVID-19 challenges China Growth continues approval for second growth in H1 World Heal
Slide 11: The Game Changer
The Game Changer The timeline compression of WHO’s 1 For personal use only 90-70-90 milestones1 to December 2030 - Sense of Urgency UNITAID and global NGOs funding 2 by late 2026 to drive cervical cancer screening 1 https://www.who.int/initiatives/cervical-cancer-elimination-initiative 11
Slide 12: Market Potential
For personal use only Market Potential 12
Slide 13: UNITAID Call for Proposals opportunity
Transformational opportunities have recently arisen through global funder UNITAID's Call for Proposals: Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries. For personal use only Three grant applications have been made by TruScreen to UNITAID to s
Slide 14: The TruScreen Technology
For personal use only The TruScreen Technology
Slide 15: How The TruScreen Device works
How The TruScreen Device works A pen-like wand covered by a Single Use Sensor (SUS) is used to gently touch multiple spots on the cervix. The Handheld device (HHD) 1 SUS contains a precision lens and electrodes which interfaces with the cervix. In doing so, it sends and picks up low level electrical
Slide 16: Instant results
Instant results TruScreen directly assesses the cervical tissue for precancerous and cancerous changes, and provides an instant result during the patient visit. For personal use only This enables immediate counselling and clinical action. It does not rely on laboratory samples such as Pap smears or
Slide 17: Device and sensor benefits
Clinicians/physicians are able to immediately plan appropriate patient care Device has an expected life span of 5–7 years Disposable SUS is used once per test per For personal use only patient - ensures there is no chance of cross- infection between patients The entire patient data collectio
Slide 18: The Global Cervical Cancer Screening Market
For personal use only The Global Cervical Cancer Screening Market
Slide 19: Cervical Cancer Is A Global Public Health Issue
Cervical Cancer Is A Global Public Health Issue† Fourth most common cancer in For personal use only Every 2 minutes, a Most diagnoses women worldwide, but preventable - in occur at working age women dies from fact only one of a handful of cancers cervical cancer. (35-44) that we understand fully. Ar
Slide 20: The Size of the Cervical Cancer Screening Market
The Size of the Cervical Cancer Screening Market • The global cervical cancer screening market is valued at ~USD 7.9 billion in 2024 - projected to reach USD 14.5 billion by 2033, an annual growth rate 2033 2024 of 5.8% (CAGR).1 • TruScreen currently makes up just 0.02% of the total market with $7.9
Slide 21: WHO & Countries are committed to eliminating Cervical Cancer
WHO & 194 Countries are committed to eliminating Cervical Cancer • In 2020 The World Health Organisation (WHO) and 194 member countries agreed on a strategy to eliminate cervical cancer this century For personal use only 90% 70% 90% 90% HPV Vaccination 70% of women screened using a high- 90% of wome
Slide 22: Why TruScreen
For personal use only Why TruScreen
Slide 23: Why TruScreen key metrics
NZ $2.4M 232 1m+ 20 For personal use only FY26E Devices operational Women Active Revenue worldwide Screened Countries • TruScreen operates in a favourable macro environment defined by the WHO 2030 90-70-90 cervical cancer elimination strategy • Unmet screening demand in low- and middle-income countr
Slide 24: Extensive body of clinical evidence
Extensive body of clinical evidence Over 40,000 women in clinical trials to date*** For personal use only Year Country Investigator N Year Country Investigator N 2002 China Dr Huang Yi 683 2019 China Dr. Baojin Wang 315 2002 China Dr Wang Ziyao 301 2019 China Dr. Wei Zhang 1030 2003 UK/Aus Prof A. S
Slide 25: COGA Trial
COGA Trial (n= 14,982, 2018-2021) 4 • COGA multicentre trial (64 hospitals, 9 provinces), represents the world’s largest opto-electronic cervical screening study • TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV • TruScreen was determined to be a simple, effective and rapid rea
Slide 26: Why TruScreen?
Why TruScreen? TruScreen Liquid Based Cytology (LBC) HPV DNA Real time results For personal use only Low infrastructure costs Strong clinical results Objective results Low training threshold Portable No cell or tissue samples taken 26
Slide 27: TruScreen Sales & Growth Strategy
For personal use only TruScreen Sales & Growth Strategy
Slide 28: Device installations and SUS Sales
Device installations and SUS Sales KEY FINANCIALS FY 23 FY 24 FY25 FY26 Actual From FY25 to FY26: NZD (m) Actual Actual Actual (unaudited) For personal use only Sales 1.66 2.1 1.7 2.4 Total Revenue 2.2 2.6 2.1 2.8 Sales increased 42% YOY COGS 1.3 1.4 1.2 1.7 R&D 0.9 0.9 0.8 0.9 SUS Sales increas
Slide 29: FY25 vs FY26 unaudited sales
FY25 ACTUAL FY26 ACTUAL NZ$1.7m Unaudited sales NZ$2.4m For personal use only 29
Slide 30: Recurring Revenue Model
Recurring Revenue Model • TruScreen manufactures two devices – o one made in China for use in China, where locally manufactured products have For personal use only preferential market access o one made in Australia for other markets • For each patient screened with the TruScreen device a new disposa
Slide 31: TruScreen Sales Strategy
TruScreen Sales Strategy • Whilst many other medical technology companies seek to commercialize their devices in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs) For personal use only such as China, Mexico, Vietnam, India, Indonesi and Zimbabwe. • Working with global
Slide 32: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: • World Health Organisation (WHO) • CE Mark, European Union • ISO 13485 For personal use only • NMPA, China • UNITAID • IEC 60601-1 • TGA, Australia • Clinton Health Access Initiative • IEC 606
Slide 33: Global presence
Global presence Registration and Sales activity in Russia, Kazakhstan, Kyrgyzstan, Armenia and Belarus Uzbekistan product registration completed to enable the validation trial of TruScreen for a national cervical cancer Inclusion in Chinese Obstetricians and screening program Gynecologists Associati
Slide 34: Growth Strategies
Growth Strategies Market expansion to continue with China the key focus For personal use only Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total population 496m Enter huge African market collaborating with NGOs Strengthen vertical Asian market from Indone
Slide 35: For personal use only
Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale Focus on countries with limited or nil cervical screening capability For personal use only Developing strategic partnerships for complementary woman’s health services Capitalise
Slide 36: DaltonBio Strategic Alliance
DaltonBio Strategic Alliance • Q4 FY25 - Memorandum of Understanding signed with Dalton Biosciences (DaltonBio) • Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for For personal use only HPV products in India 1. TruScreen to be appointed a global distributor of DaltonBio HPV related
Slide 37: Thank you.
Thank you. For personal use only Tony Ho Guy Robertson Executive Chairman Chief Financial Officer E – tonyho@truscreen.com E – guyrobertson@truscreen.com TruScreen Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Australia www.truscreen.com